Vincent T Ho

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Current and novel therapies in acute GVHD
    Vincent T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, D1B06, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 21:223-37. 2008
  2. ncbi request reprint Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies
    V T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 41:229-37. 2008
  3. ncbi request reprint Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide
    Vincent T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Semin Thromb Hemost 33:373-88. 2007
  4. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
  5. ncbi request reprint HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
    V T Ho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:845-50. 2006
  6. ncbi request reprint Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation
    Vincent T Ho
    Blood and Marrow Transplant Clinical Trials Network Toxicity Committee, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 11:571-5. 2005
  7. pmc Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:1196-204. 2011
  8. pmc Does iron overload really matter in stem cell transplantation?
    Philippe Armand
    Departments of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Am J Hematol 87:569-72. 2012
  9. pmc Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3202-8. 2012
  10. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008

Detail Information

Publications59

  1. doi request reprint Current and novel therapies in acute GVHD
    Vincent T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, D1B06, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 21:223-37. 2008
    ..In this article, we review current and novel agents available for acute GVHD, and discuss newer investigational approaches - such as phototherapy and cellular therapies - in the management of this common transplant complication...
  2. ncbi request reprint Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies
    V T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 41:229-37. 2008
    ..This article will review our current understanding of hepatic VOD, and update the clinical trial experience with DF and other potential therapies for this feared transplant complication...
  3. ncbi request reprint Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide
    Vincent T Ho
    Department of Adult Oncology, Center for Hematologic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Semin Thromb Hemost 33:373-88. 2007
    ..This article reviews our current understanding of hepatic VOD after SCT and provides a summary of the data to date on the use of DF as both therapy and prophylaxis for this disease...
  4. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
    ..The omission of mini-MTX from the Tac/Sir GVHD prophylaxis regimen appears to have no adverse effect on the development of aGVHD...
  5. ncbi request reprint HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
    V T Ho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:845-50. 2006
    ..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST...
  6. ncbi request reprint Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation
    Vincent T Ho
    Blood and Marrow Transplant Clinical Trials Network Toxicity Committee, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 11:571-5. 2005
    ..It is hoped that these positions will improve the identification and reporting of this devastating complication after hematopoietic stem cell transplantation and facilitate future clinical studies for its prevention and treatment...
  7. pmc Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:1196-204. 2011
    ..67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT...
  8. pmc Does iron overload really matter in stem cell transplantation?
    Philippe Armand
    Departments of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Am J Hematol 87:569-72. 2012
    ..These results raise the possibility that the adverse prognostic impact of pre-HSCT hyperferritinemia may be related to factors independent of iron overload...
  9. pmc Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3202-8. 2012
    ..The proteasome inhibitor bortezomib has immunomodulatory properties potentially beneficial for control of GVHD in T-cell-replete HLA-mismatched transplantation...
  10. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  11. pmc Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:792-800. 2010
    ..62, P = .03) associated with poorer PFS. RIC HSCT is well tolerated, with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not be excluded solely based on advanced patient age...
  12. pmc Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3956-9. 2009
    ..Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation. This study was registered at http://www.clinicaltrials.gov as #NCT00369226...
  13. doi request reprint Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 18:805-12. 2012
    ..Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable alternative for patients undergoing RIC HSCT without an HLA-matched donor...
  14. pmc Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis
    Joshua A Hill
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 18:1638-48. 2012
    ..1-17.3; P = .04). Death from HHV-6-PALE occurred in 50% of affected patients undergoing UCBT and no recipients of adult-donor cells. Patients receiving UCBT have increased risk for HHV-6-PALE and greater morbidity from this disease...
  15. doi request reprint Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:421-8. 2011
    ..In summary, we document a high incidence of ES after syngeneic HSCT. The trend of increased NRM after ES requires reevaluation in a larger syngeneic HSCT cohort...
  16. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  17. doi request reprint Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 19:981-7. 2013
    ..2 mg/kg versus 6.4 mg/kg) is not associated with significant differences in overall outcomes...
  18. pmc Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 112:4425-31. 2008
    ..Sirolimus-based GVHD prophylaxis without methotrexate is associated with the greatest overall survival. Myeloablative doses of busulfan should not be used with sirolimus-based immunosuppression...
  19. pmc Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:655-64. 2007
    ....
  20. pmc Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:3108-14. 2007
    ..Differences between MRD and URD cohorts are not evident when effective GVHD prophylaxis is used...
  21. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  22. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  23. pmc A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:28-35. 2008
    ....
  24. pmc Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Sci Transl Med 5:179ra43. 2013
    ..Low-dose IL-2 had minimal effects on Tcons. These findings define the mechanisms whereby low-dose IL-2 therapy restores the homeostasis of CD4(+) T cell subsets and promotes the reestablishment of immune tolerance...
  25. pmc Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation
    Bradley W Blaser
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 18:575-83. 2012
    ..Given the cardiovascular risk associated with hyperlipidemia and the tolerability of statins, further prospective evaluation of lipid abnormalities and their treatment seems well warranted...
  26. pmc Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation
    Yutaka Kawano
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 118:5021-30. 2011
    ..These results suggest that failure to activate Treg telomerase may restrict proliferative capacity and increase apoptotic susceptibility, resulting in the loss of peripheral tolerance and the development of cGVHD...
  27. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  28. pmc Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Biol Blood Marrow Transplant 18:565-74. 2012
    ..There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings...
  29. pmc Interleukin-2 and regulatory T cells in graft-versus-host disease
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 365:2055-66. 2011
    ..Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD...
  30. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  31. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
    ..039). Rituximab can prevent systemic corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in a prospective randomized trial...
  32. pmc A disease risk index for patients undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 120:905-13. 2012
    ....
  33. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
    ..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting...
  34. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
    ..These studies delineate specific abnormalities of B-cell homeostasis in patients with cGVHD and suggest that BAFF targeting agents may be useful in this disease...
  35. doi request reprint Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 17:852-60. 2011
    ..These results contribute to our understanding of the prevalence, mechanism, and consequences of iron overload in HSCT...
  36. pmc Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 120:1479-93. 2010
    ..These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations...
  37. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  38. doi request reprint Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Andrew M Brunner
    Bone Marrow Transplant Unit, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 19:1374-80. 2013
    ..Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older...
  39. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009
    ....
  40. pmc Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients
    Nicolas C Issa
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:434-8. 2011
    ..11; 95% confidence interval, 0.01-0.97). The vaccine was safe and well tolerated. Strategies are needed to improve the influenza vaccine response in this population, especially those receiving immunotherapy...
  41. pmc Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease
    Sarah Nikiforow
    Division of Hematologic Malignancies, Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Biol Blood Marrow Transplant 19:804-11. 2013
    ..The pattern of lymphocyte recovery after alemtuzumab will inform the biology and future therapy of cGVHD. The use of alemtuzumab in the context of therapy for cGVHD deserves study in larger phase II trials...
  42. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  43. pmc Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation
    Corey Cutler
    Dana Farber Cancer Institute, Boston, MA
    Blood 122:3074-81. 2013
    ..We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P = .045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants...
  44. pmc Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
    Ute E Burkhardt
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 123:3756-65. 2013
    ..We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity...
  45. ncbi request reprint Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease
    Joseph H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 10:655-68. 2004
  46. pmc Phase II trial of parathyroid hormone after double umbilical cord blood transplantation
    Karen Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, USA
    Biol Blood Marrow Transplant 18:1851-8. 2012
    ..Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery...
  47. doi request reprint Invasive fungal disease after remote inoculation in transplant recipients
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Infect Dis 52:e7-10. 2011
    ..Invasive fungal disease resulting from remote inoculation is a distinct syndrome in immunocompromised patients presenting with soft-tissue abnormalities in areas of prior trauma...
  48. doi request reprint Cord colitis syndrome in cord-blood stem-cell transplantation
    Alex F Herrera
    Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    N Engl J Med 365:815-24. 2011
    ..After the transplantation and engraftment of hematopoietic stem cells from umbilical-cord blood, we observed a new syndrome of culture-negative, antibiotic-responsive diarrhea not attributable to any known cause...
  49. doi request reprint Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation
    Sarah P Hammond
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 15:1049-59. 2009
    ..In this cohort, HBV reactivation often developed in patients with cGVHD. Liver biopsy was useful in those patients with both to delineate the contribution of each to liver dysfunction...
  50. pmc Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation
    Lee Gazourian
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women s Hospital, Boston, MA 02115, United States
    Respir Med 107:276-83. 2013
    ..There is minimal data published on quantitative radiologic characterization of airway remodeling in these subjects...
  51. pmc Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease
    Paul G Richardson
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA
    Ther Adv Hematol 3:253-65. 2012
    ..This article reviews our current understanding of VOD, and examines recent clinical findings on defibrotide for the treatment and prophylaxis of VOD...
  52. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007
    ..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures...
  53. pmc Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation
    R L Haspel
    Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
    Bone Marrow Transplant 41:523-9. 2008
    ....
  54. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
    ..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs...
  55. ncbi request reprint Donor lymphocyte infusions
    Vincent T Ho
    Bone Marrow Transplant Program, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Adv Pharmacol 51:319-45. 2004
  56. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
    ..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL...
  57. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
    ..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD...
  58. ncbi request reprint Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation
    V T Ho
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:223-9. 2001
    ..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs...
  59. pmc The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
    Gregory A Yanik
    Department of Pediatrics, University of Michigan, Ann Arbor, USA
    Blood 112:3073-81. 2008
    ..The combination of etanercept and corticosteroids is safe and is associated with high response rates and improved survival in patients with IPS...